Below is a detailed analysis of the quarterly data for Hindustan Agrigenetics Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
For Sales, as of Dec 2024, the value is 0.03 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Sep 2024) to 0.03 Cr., marking an increase of 0.03 Cr..
For Expenses, as of Dec 2024, the value is 0.24 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Sep 2024) to 0.24 Cr., marking an increase of 0.24 Cr..
For Operating Profit, as of Dec 2024, the value is -0.21 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Sep 2024) to -0.21 Cr., marking a decrease of 0.21 Cr..
For OPM %, as of Dec 2024, the value is -700.00%. The value appears to be declining and may need further review. It has decreased from 0.00% (Sep 2024) to -700.00%, marking a decrease of 700.00%.
For Other Income, as of Dec 2024, the value is 0.24 Cr.. The value appears strong and on an upward trend. It has increased from 0.15 Cr. (Sep 2024) to 0.24 Cr., marking an increase of 0.09 Cr..
For Interest, as of Dec 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
For Depreciation, as of Dec 2024, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.01 Cr..
For Profit before tax, as of Dec 2024, the value is 0.02 Cr.. The value appears to be declining and may need further review. It has decreased from 0.14 Cr. (Sep 2024) to 0.02 Cr., marking a decrease of 0.12 Cr..
For Tax %, as of Dec 2024, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00%.
For Net Profit, as of Dec 2024, the value is 0.02 Cr.. The value appears to be declining and may need further review. It has decreased from 0.14 Cr. (Sep 2024) to 0.02 Cr., marking a decrease of 0.12 Cr..
For EPS in Rs, as of Dec 2024, the value is 0.00. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
×
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: February 28, 2025, 4:11 pm
Metric
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
TTM
Sales
0.05
0.06
0.06
0.06
0.06
0.05
0.06
0.19
0.06
0.06
0.07
0.07
0.07
Expenses
0.12
0.12
0.26
0.12
0.16
0.21
0.22
0.59
0.19
0.23
0.72
0.39
0.26
Operating Profit
-0.07
-0.06
-0.20
-0.06
-0.10
-0.16
-0.16
-0.40
-0.13
-0.17
-0.65
-0.32
-0.19
OPM %
-140.00%
-100.00%
-333.33%
-100.00%
-166.67%
-320.00%
-266.67%
-210.53%
-216.67%
-283.33%
-928.57%
-457.14%
-271.43%
Other Income
-0.03
0.05
0.30
0.95
0.28
0.19
0.04
0.04
-0.05
0.06
10.56
0.96
0.56
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Depreciation
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.00
0.00
0.00
0.04
0.04
Profit before tax
-0.12
-0.03
0.09
0.88
0.17
0.02
-0.13
-0.37
-0.18
-0.11
9.91
0.60
0.33
Tax %
-66.67%
133.33%
0.00%
25.00%
35.29%
3,100.00%
-7.69%
-186.49%
-16.67%
-9.09%
0.50%
23.33%
Net Profit
-0.04
-0.07
0.09
0.66
0.11
-0.59
-0.12
0.33
-0.15
-0.10
9.86
0.47
0.33
EPS in Rs
Dividend Payout %
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
×
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
2013-2014
2014-2015
2015-2016
2016-2017
2017-2018
2018-2019
2019-2020
2020-2021
2021-2022
2022-2023
2023-2024
YoY Net Profit Growth (%)
-75.00%
228.57%
633.33%
-83.33%
-636.36%
79.66%
375.00%
-145.45%
33.33%
9960.00%
-95.23%
Change in YoY Net Profit Growth (%)
0.00%
303.57%
404.76%
-716.67%
-553.03%
716.02%
295.34%
-520.45%
178.79%
9926.67%
-10055.23%
Hindustan Agrigenetics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
Growth
Compounded Sales Growth
10 Years:
3%
5 Years:
-16%
3 Years:
10%
TTM:
14%
Compounded Profit Growth
10 Years:
%
5 Years:
%
3 Years:
%
TTM:
-166%
Stock Price CAGR
10 Years:
%
5 Years:
%
3 Years:
%
1 Year:
48%
Return on Equity
10 Years:
22%
5 Years:
28%
3 Years:
33%
Last Year:
-3%
Last Updated: Unknown
No data available for the Balance Sheet data table.
Reserves and Borrowings Chart
Cash Flow
Month
Month
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Cash from Operating Activity +
-0.07
-0.04
-0.04
-0.22
-0.10
-0.24
-0.65
1.07
5.17
-6.52
-0.42
0.07
Cash from Investing Activity +
0.03
0.06
0.05
0.21
0.12
0.22
0.89
-1.19
-0.33
11.75
-0.34
-4.40
Cash from Financing Activity +
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-0.01
Net Cash Flow
-0.04
0.02
0.01
-0.01
0.02
-0.02
0.25
-0.13
4.84
5.23
-0.76
-4.34
Free Cash Flow Chart
Financial Efficiency Indicators
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Debtor Days
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventory Days
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Days Payable
Cash Conversion Cycle
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Working Capital Days
-6,278.00
-5,170.83
-5,353.33
-730.00
-243.33
-365.00
-608.33
883.68
-4,501.67
-36,925.83
-1,668.57
9,177.14
ROCE %
0.00%
-3.51%
-2.00%
33.61%
0.00%
0.81%
-1.95%
-13.46%
-5.99%
-7.80%
-1.73%
4.96%
Financial Efficiency Indicators Chart
No valid data available for the Shareholding
Shareholding Pattern Chart
No. of Shareholders
This stock is not held by any mutual fund.
ROCE / ROE Trend
EPS Trend
Key Financial Ratios
Month
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
FaceValue
10.00
10.00
10.00
10.00
10.00
Basic EPS (Rs.)
-0.69
1.07
22.40
-0.22
-0.33
Diluted EPS (Rs.)
-0.69
1.07
22.40
-0.22
-0.33
Cash EPS (Rs.)
-0.61
1.15
22.41
-0.21
-0.32
Book Value[Excl.RevalReserv]/Share (Rs.)
27.32
27.65
26.58
4.17
4.39
Book Value[Incl.RevalReserv]/Share (Rs.)
27.32
28.02
26.95
4.55
4.77
Revenue From Operations / Share (Rs.)
0.17
2.35
24.43
0.28
0.13
PBDIT / Share (Rs.)
-0.59
1.46
22.52
-0.24
-0.40
PBIT / Share (Rs.)
-0.68
1.38
22.52
-0.25
-0.40
PBT / Share (Rs.)
-0.69
1.38
22.52
-0.25
-0.40
Net Profit / Share (Rs.)
-0.69
1.07
22.40
-0.22
-0.33
PBDIT Margin (%)
-342.41
62.20
92.19
-85.45
-288.85
PBIT Margin (%)
-388.97
58.64
92.17
-87.40
-295.28
PBT Margin (%)
-399.09
58.64
92.17
-87.40
-295.28
Net Profit Margin (%)
-395.59
45.44
91.71
-76.62
-238.42
Return on Networth / Equity (%)
-2.53
3.85
84.29
-5.28
-7.52
Return on Capital Employeed (%)
-2.42
4.91
83.54
-5.53
-8.59
Return On Assets (%)
-2.45
3.68
79.74
-1.18
-4.94
Asset Turnover Ratio (%)
0.01
0.08
1.05
0.02
0.02
Current Ratio (X)
330.73
27.72
22.40
1.11
1.92
Quick Ratio (X)
330.73
27.72
22.40
1.11
1.92
Interest Coverage Ratio (X)
-23.78
0.00
0.00
0.00
0.00
Interest Coverage Ratio (Post Tax) (X)
-26.77
0.00
0.00
0.00
0.00
Enterprise Value (Cr.)
24.41
13.01
-8.02
0.00
0.00
EV / Net Operating Revenue (X)
316.56
12.59
-0.74
0.00
0.00
EV / EBITDA (X)
-92.45
20.24
-0.80
0.00
0.00
MarketCap / Net Operating Revenue (X)
383.23
21.77
0.20
0.00
0.00
Price / BV (X)
2.46
1.85
0.19
0.00
0.00
Price / Net Operating Revenue (X)
383.71
21.77
0.20
0.00
0.00
EarningsYield
-0.01
0.02
4.44
0.00
0.00
After reviewing the key financial ratios for Hindustan Agrigenetics Ltd, here is a detailed analysis based on the latest available data and recent trends:
For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 5. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
For Diluted EPS (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 5. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
For Cash EPS (Rs.), as of Mar 25, the value is -0.61. This value is below the healthy minimum of 3. It has decreased from 1.15 (Mar 24) to -0.61, marking a decrease of 1.76.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 27.32. It has decreased from 27.65 (Mar 24) to 27.32, marking a decrease of 0.33.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 27.32. It has decreased from 28.02 (Mar 24) to 27.32, marking a decrease of 0.70.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.17. It has decreased from 2.35 (Mar 24) to 0.17, marking a decrease of 2.18.
For PBDIT / Share (Rs.), as of Mar 25, the value is -0.59. This value is below the healthy minimum of 2. It has decreased from 1.46 (Mar 24) to -0.59, marking a decrease of 2.05.
For PBIT / Share (Rs.), as of Mar 25, the value is -0.68. This value is below the healthy minimum of 0. It has decreased from 1.38 (Mar 24) to -0.68, marking a decrease of 2.06.
For PBT / Share (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 0. It has decreased from 1.38 (Mar 24) to -0.69, marking a decrease of 2.07.
For Net Profit / Share (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 2. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
For PBDIT Margin (%), as of Mar 25, the value is -342.41. This value is below the healthy minimum of 10. It has decreased from 62.20 (Mar 24) to -342.41, marking a decrease of 404.61.
For PBIT Margin (%), as of Mar 25, the value is -388.97. This value is below the healthy minimum of 10. It has decreased from 58.64 (Mar 24) to -388.97, marking a decrease of 447.61.
For PBT Margin (%), as of Mar 25, the value is -399.09. This value is below the healthy minimum of 10. It has decreased from 58.64 (Mar 24) to -399.09, marking a decrease of 457.73.
For Net Profit Margin (%), as of Mar 25, the value is -395.59. This value is below the healthy minimum of 5. It has decreased from 45.44 (Mar 24) to -395.59, marking a decrease of 441.03.
For Return on Networth / Equity (%), as of Mar 25, the value is -2.53. This value is below the healthy minimum of 15. It has decreased from 3.85 (Mar 24) to -2.53, marking a decrease of 6.38.
For Return on Capital Employeed (%), as of Mar 25, the value is -2.42. This value is below the healthy minimum of 10. It has decreased from 4.91 (Mar 24) to -2.42, marking a decrease of 7.33.
For Return On Assets (%), as of Mar 25, the value is -2.45. This value is below the healthy minimum of 5. It has decreased from 3.68 (Mar 24) to -2.45, marking a decrease of 6.13.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.01. It has decreased from 0.08 (Mar 24) to 0.01, marking a decrease of 0.07.
For Current Ratio (X), as of Mar 25, the value is 330.73. This value exceeds the healthy maximum of 3. It has increased from 27.72 (Mar 24) to 330.73, marking an increase of 303.01.
For Quick Ratio (X), as of Mar 25, the value is 330.73. This value exceeds the healthy maximum of 2. It has increased from 27.72 (Mar 24) to 330.73, marking an increase of 303.01.
For Interest Coverage Ratio (X), as of Mar 25, the value is -23.78. This value is below the healthy minimum of 3. It has decreased from 0.00 (Mar 24) to -23.78, marking a decrease of 23.78.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -26.77. This value is below the healthy minimum of 3. It has decreased from 0.00 (Mar 24) to -26.77, marking a decrease of 26.77.
For Enterprise Value (Cr.), as of Mar 25, the value is 24.41. It has increased from 13.01 (Mar 24) to 24.41, marking an increase of 11.40.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 316.56. This value exceeds the healthy maximum of 3. It has increased from 12.59 (Mar 24) to 316.56, marking an increase of 303.97.
For EV / EBITDA (X), as of Mar 25, the value is -92.45. This value is below the healthy minimum of 5. It has decreased from 20.24 (Mar 24) to -92.45, marking a decrease of 112.69.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 383.23. This value exceeds the healthy maximum of 3. It has increased from 21.77 (Mar 24) to 383.23, marking an increase of 361.46.
For Price / BV (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has increased from 1.85 (Mar 24) to 2.46, marking an increase of 0.61.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 383.71. This value exceeds the healthy maximum of 3. It has increased from 21.77 (Mar 24) to 383.71, marking an increase of 361.94.
For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to -0.01, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
×
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Error: Data is incomplete for fair value calculation.
Strength and Weakness
Unable to fetch valid data for stock valuation.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hindustan Agrigenetics Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: -2.53% (Industry Average ROE: 3.04%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 0 (Industry average Stock P/E: 11.2)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Hindustan Agrigenetics Ltd. is a Public Limited Listed company incorporated on 25/07/1990 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L01119DL1990PLC040979 and registration number is 040979. Currently company belongs to the Industry of Floriculture. Company's Total Operating Revenue is Rs. 0.08 Cr. and Equity Capital is Rs. 4.40 Cr. for the Year ended 31/03/2025.
FAQ: Stock data is invalid or not in the correct format.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Hindustan Agrigenetics Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE